{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-037627","form_type":"8-K","ticker":"ACRV","cik":"0001781174","company_name":"Acrivon Therapeutics, Inc.","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.499577+00:00","generated_at":"2026-06-04T06:22:35.154058+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Acrivon reports Q4 2023 net loss of $19.3M; cash runway into Q4 2025","bullets":["Net loss Q4 2023 $19.3M, full year $60.4M; R&D expenses $15.5M/$46.0M.","Cash, equivalents and marketable securities $127.5M at Dec 31, 2023; funds operations into Q4 2025.","ACR-368 Phase 2 trial enrolling; Phase 1b combo with gemcitabine completed; ACR-2316 IND studies advancing.","Two abstracts accepted for AACR 2024 on ACR-2316 and ACR-368 resistance mechanism.","Appointed Jean-Marie Cuillerot as CMO; added two new board members."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-037627","json":"https://secwatch.observer/filing/0000950170-24-037627.json","markdown":"https://secwatch.observer/filing/0000950170-24-037627.md","text":"https://secwatch.observer/filing/0000950170-24-037627.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781174/000095017024037627/0000950170-24-037627-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781174/000095017024037627/acrv-20240328.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T06:22:35.154058+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"730503b1eac829527acbecceff596065c886659f","claim":"Acrivon Therapeutics, Inc. reported fourth quarter and full year ended December 31, 2023 results: net income $19.3 million and $60.4 million, respectively.","evidence_excerpt":"Net loss for the quarter and full year ended December 31, 2023 was $19.3 million and $60.4 million, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781174/000095017024037627/0000950170-24-037627-index.htm","confidence":0.92,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2023"},{"label":"Net income","value":"$19.3 million and $60.4 million, respectively"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}